Yimiao Shenzhou Secures Spot on BIOCHINA's Top 100 Most Innovative Companies for Second Consecutive Year
Imunopharm
Developer of Gene and Cell Therapy Technologies
On March 15, 2024, the 2024 BIOCHINA 9th EMBIO Biotechnology Industry Conference, hosted by EMBIO Medical, officially opened at the Suzhou International Expo Center. The organizing committee announced the EMBIO Biotechnology Industry Annual Awards "BIOCHINA Awards" series. Beijing Yimiaoshenzhou Medical Techology Co., Ltd., recognized for its innovation and breakthroughs in the gene and cell therapy field over the past year, was selected by expert judges to be listed on the BIOCHINA Awards for the second consecutive year, earning a spot among the Top 100 Innovative Breakthrough Companies of 2023. The company's CEO, Dr. He Ting, attended the conference and received the award trophy on-site.
Dr. He Ting, CEO of the company, attended the award ceremony (5th from the left).
This award was selected by the BIOCHINA Organizing Committee in collaboration with the Special Committee based on the principles of fairness, impartiality, and transparency. The selection was data-driven, utilizing comprehensive evaluations from multiple dimensions of authentic data. The assessment reviewed the company’s overall situation in 2023 (including basic company status, industry position, business model, revenue performance, etc.) and industry competitiveness (comprehensive background, brand influence, management capability), among other criteria.
In March 2023, Beijing Yimiaoshenzhou Medical Techology Co., Ltd. was listed among the top 100 innovative breakthrough companies of 2022. This year, it has made the list again, which is an ongoing affirmation from the industry for the company's long-term independent research and development in gene and cell-based pharmaceuticals. In 2023, Yimiao Shenzhou achieved several significant breakthroughs and milestones in the development of new technology platforms and product pipelines for gene and cell-based drugs: the company’s self-developed cutting-edge CAR-T cell technology platform obtained...Top Prize Winner of the Final Round of China's Disruptive Technology Innovation Competition; Solid Tumor CAR-T ProductsIM83 Granted Two Clinical Trial Approvals by the National Medical Products Administration (NMPA); IM96 for the treatment of advanced metastatic colorectal cancerClinical Research Achieves Breakthrough Progress, Relevant Data Presented at EMSO 2023 Annual Meeting; The first CAR-T cell drugClinical Trials of IM19 Progressing Smoothly, which is expected to be submitted for product marketing authorization application this year. It is hoped that it will become the first original CAR-T cell therapy drug approved for marketing in its class for the treatment of advanced lymphoma, benefiting hundreds of thousands of patients with malignant lymphoma.
// About Yimiao Shenzhou //
Founded in 2015, Beijing Yimiaoshenzhou Medical Technology Co., Ltd. is headquartered in Beijing and has the mission of "making cancer no longer an incurable disease." It is a leading innovative pharmaceutical company at the clinical stage, focusing on applying cutting-edge gene and cell drug technologies to treat major diseases (such as cancer and autoimmune diseases). To date, the company has completed nine rounds of strategic financing and owns a one-stop independent gene and cell drug R&D and industrialization platform. It has mastered several core technologies, won the highest prize (excellent award) in the finals of China's Disruptive Technology Innovation Competition, obtained five clinical trial approvals for Class 1 new drugs, and received Beijing’s first Drug Manufacturing License for gene and cell drugs. Its R&D pipeline covers hematological tumors such as lymphoma, leukemia, and myeloma, as well as solid tumors like liver cancer, colorectal cancer, gastric cancer, and pancreatic cancer. The company is a leader in the field of gene and cell drugs.
The company has undertaken more than 10 national and provincial-level scientific research projects, including the Special Project of the National Key R&D Program by the Ministry of Science and Technology, the "Challenge to Lead" technical project for cell therapy by the National Innovation Center under the Ministry of Science and Technology, and the Beijing Municipal Science and Technology Major Project. It is a National High-tech Enterprise, a Beijing-based specialized, refined, distinctive, and innovative enterprise, a Frontier Technology Enterprise in Zhongguancun, a Zhongguancun High-tech Enterprise, and a Postdoctoral Research Station. The team has been honored with awards such as Beijing Science and Technology Nova, Zhongguancun High-end Leading Talent, Beijing Haiying Talent, Xinguomen Leading Talent, the Gold Award (First Place) at Tsinghua University President’s Cup Innovation Challenge, MIT Technology Review's 35 Innovators Under 35, and Fortune Magazine's 40 Under 40 Business Elites.
